CEOCFO Magazine,
Phone: 727-480-7070

Email: info@ceocfocontact.com

Weekly Digital Publication IN-DEPTH INTERVIEWS WITH Top   CORPORATE EXECUTIVES (727) 480-7070 info@ceocfocontact.com FIND INTERVIEWS AND ARTICLES

Business Services | Solutions

Medical | Biotech

Cannabis  | Psychedelics

Banking | FinTech | Capital

Government Services

Public Companies

Industrial | Resources

Clean Tech

Global | Canadian



Lynn Fosse, Senior Editor

Steve Alexander, Associate Editor

Bud Wayne, Editorial Executive

Christy Rivers - Editorial Executive

Valerie Austin - Editorial Associate


HOME

CURRENT ISSUE

INTERVIEW INDEX

CEOCFO SERVICES

CEOCFO MOBILE


Public Companies | Investment Opportunities  



GB Sciences – using Minimum Essetial Mixtures (MEM) to Harness the Therapeutic Potential of Plant-Inspired Medicines as Prescription Drugs


GB Sciences, Inc.

OTCMKTS: GBLX
Dr. Andrea Small-Howard, President & CSO

https://www.gbsciences.com/

- Print - PDF  Mobile - PD




___________________________________________________


Serving the Trade Credit and Supply Chain Risk Markets, CreditRiskMonitor is helping Public Corporations and B2Bs Analyze Financial Risk


CreditRiskMonitor

(OTCQX:CRMZ)

Mike Flum, President & COO

https://www.creditriskmonitor.com/



- CreditRiskMonitor® Print - PDF

- SupplyChainMonitor™ Mobile - PDF


______________________________________________________


C-COM Satellite Systems starts 2022 with Significant Orders


C-COM Satellite Systems Inc.

(TSXV: CMI) (OTCQB: CYSNF)

Dr. Leslie Klein, President and CEO

https://www.c-comsat.com/


- Print - PDF  Mobile - PDF




______________________________________________________








Maximize your profitability with anytime access to your own secure, online merchant portal! Leverage all the industry-leading perks, tools, and solutions you need to streamline your operations. Call NOW 727-480-7070






New CEO Focuses on Advancing Antibody Drugs to Fight Alzheimer’s Disease and Other Neurodegenerative Conditions


ProMIS Neurosciences, Inc.

(Nasdaq: PMN)

Neil Warma, CEO


www.promisneurosciences.com

- Print - PDF Mobile - PDF